Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,992.00GBp
9:05pm IST
Change (% chg)

1.00 (+0.02%)
Prev Close
4,991.00
Open
5,009.00
Day's High
5,025.00
Day's Low
4,973.00
Volume
1,829,710
Avg. Vol
2,048,091
52-wk High
5,585.07
52-wk Low
4,260.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 30.95 32.74
EPS (TTM): 2.34 -- --
ROI: 7.86 14.84 14.38
ROE: 28.47 16.34 16.07

AstraZeneca raises stake in respiratory partner Circassia

LONDON AstraZeneca is paying up to $45 million to increase its stake in Circassia , backing a company seeking to bounce back from the failure of its allergy drugs by switching all of its focus to respiratory medicines.

24 Apr 2018

UPDATE 1-AstraZeneca raises stake in respiratory partner Circassia

LONDON, April 24 AstraZeneca is paying up to $45 million to increase its stake in Circassia, backing a company seeking to bounce back from the failure of its allergy drugs by switching all of its focus to respiratory medicines.

24 Apr 2018

AstraZeneca flop a fresh blow to cancer immunotherapy combination

LONDON The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study.

24 Apr 2018

UPDATE 1-AstraZeneca flop a fresh blow to cancer immunotherapy combination

* AstraZeneca raises stake in Circassia to 19.9 pct (Adds market reaction, context on other companies)

24 Apr 2018

BRIEF-Redx Pharma Appoints Astrazeneca Executive Lisa Anson As CEO

* REDX PHARMA PLC - REDX APPOINTS SENIOR ASTRAZENECA EXECUTIVE AS CEO

24 Apr 2018

AstraZeneca third-line lung cancer combination study fails

LONDON, April 24 A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping patients live longer.

24 Apr 2018

AstraZeneca to raise stake in Circassia to up to 19.9 pct

LONDON, April 24 British pharmaceutical company AstraZeneca said it would subscribe for more shares in Circassia by injecting cash into the respiratory drug specialist to take its stake to a maximum of 19.9 percent from 14.2 percent.

24 Apr 2018

BRIEF-AstraZeneca disappointed by data from Arctic trial in third-line non-small cell lung cancer

* REPORTS RESULTS FROM ARCTIC TRIAL IN THIRD-LINE NON-SMALL CELL LUNG CANCER

24 Apr 2018

AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

19 Apr 2018

UPDATE 1-AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

April 18 U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

19 Apr 2018

Earnings vs. Estimates